Eman I. Elberri
Tanda, GH, Egypt
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Immunomodulatory and Anti-Inflammatory Effects of Ketotifen Versus Vitamin E in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Pilot Study.
Journal: Drug design, development and therapy
Published: January 04, 2026
Ketotifen for Preventing Oxaliplatin-Induced Neuropathy in Stage III Colorectal Cancer: a Randomized Controlled Trial.
Journal: Journal of gastrointestinal cancer
Published: November 28, 2025
Randomized, double-blind, placebo-controlled pilot study of metformin as an adjunctive therapy in Parkinson's disease.
Journal: Frontiers in pharmacology
Published: September 16, 2024
Fenofibrate as an Adjunct Therapy for Ulcerative Colitis: Targeting Inflammation via SIRT1, NLRP3, and AMPK Pathways: A Randomized Controlled Pilot Study.
Journal: Drug design, development and therapy
Published: August 09, 2024
Corrigendum: Effect of a high dose atorvastatin as added-on therapy on symptoms and serum AMPK/NLRP3 inflammasome and IL-6/STAT3 axes in patients with major depressive disorder: randomized controlled clinical study.
Journal: Frontiers in pharmacology
Published: July 13, 2024
A randomized controlled trial comparing tacrolimus versus hydrocortisone for the treatment of atopic dermatitis in children: new perspectives on interferon gamma-induced protein and growth-related oncogene-α.
Journal: Frontiers in medicine
Published: March 11, 2024
Effect of a high dose atorvastatin as added-on therapy on symptoms and serum AMPK/NLRP3 inflammasome and IL-6/STAT3 axes in patients with major depressive disorder: randomized controlled clinical study.
Journal: Frontiers in pharmacology
Published: February 03, 2024
Tacrolimus versus hydrocortisone in management of atopic dermatitis in children, a randomized controlled double-blind study: New insights on TARC, CTACK, TSLP, and E-selectin.
Journal: Immunity, inflammation and disease
Published: October 09, 2023
A randomized placebo-controlled, double-blind study to investigate the effect of a high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients, new insights on serum STAT-3 and hepassocin.
Journal: European review for medical and pharmacological sciences
Published: September 05, 2023
Showing 1-9 of 9
Last Updated: 09/26/2026